Trial Profile
An observational study of KPL-716 in patients with prurigo nodularis
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Aug 2018
Price :
$35
*
At a glance
- Drugs Vixarelimab (Primary)
- Indications Prurigo nodularis
- Focus Adverse reactions; Therapeutic Use
- Acronyms LOTUS-PN
- 13 Aug 2018 New trial record
- 06 Aug 2018 According to a Kiniksa Pharmaceuticals media release, the company completed enrolment of this trial in the second quarter of 2018.